A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes
Completed · Phase 3 · NCT05872620
Conditions: Obesity, Overweight, Type 2 Diabetes
At a glance
- Research payments reported, 2025
- $4.8M
- U.S. investigators named
- 47
- Sites paid
- 47
- Planned or actual enrollment
- 1,613
About the trial
- Sponsor
- Eli Lilly and Company
- Tested
- Orforglipron (drug), Placebo (drug)
- Dates
- Started 2023-06-05; completion 2025-08-08
- Results posted
- Yes
This study will investigate the safety and efficacy of once daily oral treatment with orforglipron compared with placebo on body weight in adult participants with obesity or overweight and type 2 diabetes. The study will last about 77 weeks and may include up to 22 visits.
From ClinicalTrials.gov, last updated 2026-09-04. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $4.8M in research payments for this study in 2025 (89 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Jitendra Sharma, M.B.B.S Neurology · Birmingham, AL
- Michael S. Vaughn, M.D. Family Medicine · Birmingham, AL
- Thili N. Kulatilake, M.D. Family Medicine · Tucson, AZ
- Robert F. Smythe, M.D. Internal Medicine · Yuma, AZ
- Timothy S. Bailey, M.D. Endocrinology & Diabetes · Escondido, CA
- David L. Guzman, D.P.M. Podiatrists · Napa, CA
- Stanley Hsia, M.D. Endocrinology & Diabetes · Los Angeles, CA
- Rizwana Mohseni, D.O. Family Medicine · Lake Forest, CA
- Joanna T. Van, DO Family Medicine · Colton, CA
- Adline Ghazi, M.D. Endocrinology & Diabetes · Washington, DC
- Cathy B. Barnes, MD Family Medicine · New Port Richey, FL
- Juan P. Loy, M.D. Internal Medicine · Margate, FL
- J S. Magee, M.D. Endocrinology & Diabetes · Jacksonville, FL
- Rodolfo A. Perez, M.D. Specialist · Hialeah, FL
- Nadia G. Cameron, M.D. Family Medicine · Lawrenceville, GA
- John Chip H. Reed III, M.D. Endocrinology & Diabetes · Roswell, GA
- Bram Wieskopf, MD Internal Medicine · Woodstock, GA
- Alan Parsa, M.D. Endocrinology & Diabetes · Honolulu, HI
- Anuj Bhargava, MD Endocrinology & Diabetes · West Des Moines, IA
- David Butuk, MD Family Medicine · Meridian, ID
- Neil J. Fraser, MD Internal Medicine · Troy, MI
- Timothy R. Smith, M.D. Internal Medicine · Saint Peters, MO
- John Rubino, MD Internal Medicine · Raleigh, NC
- William T. Smith IV, MD Cardiac Electrophysiology · Wilmington, NC
- Trent L. Wei, MD Interventional Cardiology · Greensboro, NC
- Yaw A. Adjei-poku, M.D. Cardiac Electrophysiology · Albuquerque, NM
- Cornell V. Calinescu, MD Emergency Medicine · Las Vegas, NV
- Robert S. Busch, M.D. Endocrinology & Diabetes · Albany, NY
- Bliss J. Chang, MD Cardiology · Albany, NY
- Anastasios Manessis, MD Endocrinology & Diabetes · New York, NY
- Robert E. Dunn, MD Cardiac Electrophysiology · Cleveland, OH
- Medhat Farwati, MD Student in an Organized Health Care Education/Training Program · Cleveland, OH
- Devora Lichtman, MD Internal Medicine · Cleveland, OH
- Beal Essink, MD Psychiatry · Salem, OR
- Angel L. Comulada Endocrinology & Diabetes · Bayamon, PR
- Paola Mansilla-letelier, M.D Endocrinology & Diabetes · Guaynabo, PR
- Felix O. Berglund, MD Cardiology · Nashville, TN
- Zackary D. Goff, M.D. Cardiology · Nashville, TN
- Aidar R. Gosmanov, M.D., PH.D. Endocrinology & Diabetes · Memphis, TN
- Hareshkumar D. Boghara, M.D. Family Medicine · Desoto, TX
- Hesham M. Elgouhari, M.D. Hepatology · Denison, TX
- Donald F. Gardner, MD Specialist · Houston, TX
- Juan M. Garza JR., M.D. Emergency Medicine · San Antonio, TX
- Mark S. Kipnes, MD Endocrinology & Diabetes · San Antonio, TX
- Julio Rosenstock, M.D. Endocrinology & Diabetes · Dallas, TX
- James R. Clark, MD Internal Medicine · Charlottesville, VA
- Sabrina A. Benjamin, MD Internal Medicine · Olympia, WA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Velocity Clinical Research Inc $338,415
- Vip Trials LLC $302,642
- North Georgia Clinical Research $301,918
- Fisher Scientific Co LLC $250,578
- Advanced Clinical Research LLC $229,596
- Epic Medical Research $205,865
- Arcturus Healthcare PLC, Troy Internal $179,554
- Nyc Research Inc $173,304
- Encore Medical Research, LLC $170,437
- Alliance for Multispecialty Research Lls $151,851
- Summit Headlands LLC $150,679
- Piedmont Medical Research Associates Inc $139,407
- Biopharma Informatic Inc $132,817
- Studymetrix Research LLC $130,631
- Catalina Research Institute LLC $130,612
- Las Vegas Medical Research LLC $130,066
- Ima Evaluations LLC DBA Ima Clinical Research $129,126
- Medstar Health Research Institute $127,288
- Suncoast Clinical Research $123,927
- Novak Clinical Research $111,296
- Albany Stratton VA Medical Center $107,140
- Iowa Diabetes and Endocrinology Rsrch Cntr $103,019
- University Clinical Investigators Inc $100,067
- Headlands Research California LLC $94,177
- South Florida Wellness and Clinical Resear $93,778
- Pacific Diabetes and Endocrine Center $92,262
- Solaris Clinical Research LLC $86,811
- Cahaba Research $85,172
- Universal Research Group LLC $83,598
- Yuma Clinical Trials LLC $79,835
- East Coast Institute for Research $75,433
- Soma Clinical Trials LLC $61,489
- Sky Clinical Research Network Group $51,386
- Clark Medical Research LLC $39,565
- Albany Medical College $28,681
- Diabetes & Glandular Disease $15,088
- Endocrine Research Solutions Inc $5,895
- Cleveland Clinic, OH $3,402
- Albuquerque Neuroscience Inc $1,609
- Capital Clinical Research Center PLLC $1,190
- Jeffrey B Rosen MD PA DBA Clinical Research of South $1,063
- Intend Research LLC $465
- Diabetes and Glandular Disease Ctr $436
- Rheumatology Center of Houston $430
- Andrew J Lewin Med DBA National Rsrch Institute $430
- Amcr Institute Inc $430
- Dallas Diabetes and Endo Research Center PA $409
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.